|
WO2020150114A1
|
|
Heterocyclic nlrp3 modulators, for use in the treatment of cancer
|
|
WO2020150115A1
|
|
Nlrp3 modulators
|
|
WO2020150116A1
|
|
Nlrp3 modulators
|
|
WO2020150113A1
|
|
Substituted quinazolines as nlrp3 modulators, for use in the treatment of cancer
|
|
WO2020037092A1
|
|
Imidazo[4,5-c]quinoline derived nlrp3-modulators
|
|
WO2020037091A1
|
|
Imidazo[4,5-c]quinoline derived nlrp3-modulators
|
|
SG11202101486RA
|
|
Substitued 4-amino-1h-imidazo[4,5-c]quinoline compounds and improved methods for their preparation
|
|
CN112074516A
|
|
NLRP3 modulators
|
|
AU2018301681A1
|
|
NLRP3 modulators
|
|
TW201835077A
|
|
Nlrp3 modulators
|
|
KR20180134395A
|
|
NLRP3 modulator
|
|
US2019031708A1
|
|
Cyclic dinucleotides for treating conditions associated with STING activity such as cancer
|
|
AU2017207757A1
|
|
Cyclic dinucleotides for treating conditions associated with STING activity such as cancer
|
